ClinicalTrials.gg
RecruitingNCT05962879Updated Jun 11, 2026

Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness

An interventional study of Resilience Training for Teens in Anxiety Disorders, Psychotic Disorders and Depressive Disorder, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 14 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
14 Years to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Anxiety Disorders by Massachusetts General Hospital — 14 open to participants now, 20 under way, none of them phase 3. Anxiety Disorders · Massachusetts General Hospital.

Planned enrollment
30th of 64
70 · median 63
Started
2024
with 5 others
No phase
40 of 67
12 open now
Primary completion
2027-05
later than 9 of 19 live
Registered
51st of 67
by date

Among the 67 studies in Anxiety Disorders by Massachusetts General Hospital, this one is the 30th largest by planned enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2024, is one of 40 with no phase, reaches primary completion later than 9 of the 19 other live ones, and was the 51st registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

14 of the 67 studies in Anxiety Disorders by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 14 Years to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Anxiety Disorders by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This research study aims to develop a brief group-based treatment called Resilience Training for Teens, then to test how well it protects high school students with mild symptoms of depression, anxiety, or having unusual feelings from developing mental illnesses.

03

Conditions studied

  • Anxiety Disorders
  • Psychotic Disorders
  • Depressive Disorder
  • Psychosocial Functioning
04

Who can participate

Ages eligible
14 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently enrolled in 9th through 12th grade and between the ages of 14 and 19
  • Endorsed at least one psychotic experience
  • Provided contact information
  • Have a parent or legal guardian who is able and willing to provide written (if under the age of 18)
  • Have a parent or legal guardian who is able and willing to participate in a parent session
  • Competent and willing to provide written informed assent (if under the age of 18) or consent (if age 18 or older)
  • Able to communicate in English

Exclusion criteria

Exclusion Criteria:

  • Currently prescribed psychotropic medication (not including medications for attention deficit/hyperactivity disorder), regardless of adherence
  • Currently obtaining psychotherapeutic intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Resilience Training for Teens

    A brief 6-session group-based behavioral intervention for teens at risk of a mental illness.

    Behavioral: Resilience Training for Teens

  • No intervention
    Waitlist

    A one year waitlist period where participants will not participate in Resilience Training for Teens. Following that one year waitlist period, they can participate in Resilience Training for Teens.

Interventions

  • BehavioralResilience Training for Teens

    A brief 6-session group-based behavioral intervention for high school aged teenagers at risk of a mental illness.

06

What researchers measure

Primary outcomes

  1. Structured Interview of Psychosis-risk Syndromes (SIPS)

    Subclinical psychotic symptoms that represent a risk of transdiagnostic mental illnesses. This semi-structured interview rates psychotic experiences, general symptoms, and functioning. The SIPS interview assesses positive, negative, disorganized, and general symptoms. The range of the Scale of Psychosis-risk Symptoms (SOPS) is 0-6, with a higher score representing more severe symptoms.

    Time frame: 1 year

Secondary outcomes

  1. Child Behavior Checklist (CBCL)

    Mental health symptoms in the teen rated by both the teen and the parent/guardian consisting of 113 items. The CBCL rates multiple domains across functioning and psychiatric diagnoses. It is scored on a 3-point Likert scale, with higher scores representing more severe symptoms.

    Time frame: 1 year

  2. Global Functioning Social and Role Scales

    Social and school/work functioning captured on this scale rated on a 10 point likert scale assessing functional and social functioning separately. Higher ratings represent richer functioning.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 38 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Jul 27, 2023
StartActual
Mar 22, 2024
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05962879
Responsible party
Nicole DeTore, PhD (Assistant Professor, Massachusetts General Hospital) — Principal investigator
First posted
Jul 27, 2023
Start date
Mar 22, 2024
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 11, 2026

Study contacts

Nicole R DeTore, PhD
Contact
ndetore@mgh.harvard.edu
617-726-2065

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion